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Figure and Table Legends 
 
Figure 1. EB-NCT procedure.  
18F-labeled positron emission tomography (PET) was performed prior to external beam 
NCT (EB-NCT) in order to calculate the lesion-to-normal ratio of BPA-mediated 10B, 
followed by debulking surgery. BSH (5 g/body) and BPA (250 mg/kg) were intravenously 
injected before neutron irradiation. Blood samples were drawn serially after intravenous 
injection to estimate the total blood boron level. Neutron irradiation was performed in a 
single fraction using an epithermal beam of Japan Research Reactor No. 4 (JRR-4). 
 
Figure 2. Kaplan-Meier estimation of overall survival (OS) and time to tumor progression 
(TTP) according to treatment group. 
OS for the all patients (thick solid line), Protocol-1 (thick broken line) and Protocol-2 
(thick dotted line), and TTP for the all patients (fine solid line), Protocol-1 (fine broken 
line) and Protocol-2 (fine dotted line) are shown. The number of patients at risk shows 
values at NCT (in parentheses), at 6 months and every 6 months. The median OS and TTP 
were 23.3 M and 12.0 M for protocol-1, and 27.1 M and 11.9 M for protocol-2, respectively. 
The 1- and 2-year survival rates for all patients were 80.0% and 53.3%, respectively. 
 
Table 1. Characteristics of the present 15 patients with newly diagnosed, histologically 
confirmed glioblastoma who were treated with boron neutron capture therapy.  
  All patients underwent surgical removal before BNCT, which consisted of gross total 
removal in 4 (26.7%), partial removal in 10 (66.7%) and biopsy in 1 (6.6%). Two of 15 
patients (13.3%) were categorized in the best prognostic group of GBM (class III) by the 
Radiation Therapy Oncology Group (RTOG) Recursive Partitioning Analysis (RPA) as 
were 3 of 15 patients (20%) by the European Organization for Research and Treatment of 
Cancer (EORTC) RPA. 
 
